Sign Up to like & get
recommendations!
0
Published in 2019 at "Urology"
DOI: 10.1016/j.urology.2019.05.012
Abstract: OBJECTIVE To investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists. METHODS…
read more here.
Keywords:
enzalutamide urologists;
abiraterone enzalutamide;
enzalutamide;
adoption abiraterone ... See more keywords